Zintevir AR177 oligonucleotide blocker of HIV integrase enzyme data

ARNX published Phase I and animal results with Zintevir, a blocker of the enzyme required by HIV for integration into human DNA. As reported in The Journal of Pharmacology and Experimental Therapeutics, intravenous use in monkeys showed tolerability and pharmacokinetics that have been reproduced in HIV-positive people.

Phase I testing of 0.75-3 mg/kg gave no adverse effects. In addition, concentrations in plasma exceeding the 50 percent inhibitory concentrations in vitro were achieved for more than six hours. Dose escalation testing is in progress with evaluation of safety, pharmacokinetics and viral load. ...